mitomycin has been researched along with Astrocytoma, Grade IV in 5 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We compared the cytotoxicity of the bioreductive antitumor agents mitomycin C (MMC) and streptonigrin (SN) with or without the DT-diaphorase (DTD) inducer dimethyl fumarate (DMF) in four human glioblastoma cell lines with the conventional chemotherapeutic agent, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)." | 7.73 | Enhanced cytotoxicity of bioreductive antitumor agents with dimethyl fumarate in human glioblastoma cells. ( DeAngelis, LM; Gu, B, 2005) |
| "We compared the cytotoxicity of the bioreductive antitumor agents mitomycin C (MMC) and streptonigrin (SN) with or without the DT-diaphorase (DTD) inducer dimethyl fumarate (DMF) in four human glioblastoma cell lines with the conventional chemotherapeutic agent, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)." | 3.73 | Enhanced cytotoxicity of bioreductive antitumor agents with dimethyl fumarate in human glioblastoma cells. ( DeAngelis, LM; Gu, B, 2005) |
| "Cytotoxic T lymphocytes (CTL) against autologous malignant brain tumor were generated in peripheral blood lymphoid cells (PBL) prepared from a patient with a malignant brain tumor by stimulation of the cultured PBL for 7 days with attenuated crossreactive malignant melanoma (MM2) cells pretreated with mitomycin C." | 3.69 | Induction of specific cytotoxic T lymphocytes against autologous brain tumor by crossreactive allo-tumor cell stimulation. ( Fujimoto, S; Kurisaka, M; Maeda, N; Mori, K; Saitoh, S, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gu, B | 1 |
| DeAngelis, LM | 1 |
| Halperin, EC | 1 |
| Herndon, J | 1 |
| Schold, SC | 1 |
| Brown, M | 1 |
| Vick, N | 1 |
| Cairncross, JG | 1 |
| Macdonald, DR | 1 |
| Gaspar, L | 1 |
| Fischer, B | 1 |
| Dropcho, E | 1 |
| Rosenfeld, S | 1 |
| Morowitz, R | 1 |
| Piepmeier, J | 1 |
| Hait, W | 1 |
| Byrne, T | 1 |
| Salter, M | 1 |
| Imperato, J | 1 |
| Khandekar, J | 1 |
| Paleologos, N | 1 |
| Burger, P | 1 |
| Bentel, GC | 1 |
| Friedman, A | 1 |
| Stewart, DJ | 1 |
| Dahrouge, S | 1 |
| Agboola, O | 1 |
| Girard, A | 1 |
| Saitoh, S | 1 |
| Kurisaka, M | 1 |
| Mori, K | 1 |
| Maeda, N | 1 |
| Fujimoto, S | 1 |
| Okamura, T | 1 |
| Kurisu, K | 1 |
| Yamamoto, W | 1 |
| Takano, H | 1 |
| Nishiyama, M | 1 |
2 trials available for mitomycin and Astrocytoma, Grade IV
| Article | Year |
|---|---|
A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. CNS Cancer Consortium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 1996 |
Cranial radiation and concomitant cisplatin and mitomycin-C plus resistance modulators for malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta Carotene; Brain Neoplasms; Cisplat | 1997 |
3 other studies available for mitomycin and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Enhanced cytotoxicity of bioreductive antitumor agents with dimethyl fumarate in human glioblastoma cells.
Topics: Antineoplastic Agents; Carmustine; Cell Death; Cell Line, Tumor; Cytochrome-B(5) Reductase; Dicumaro | 2005 |
Induction of specific cytotoxic T lymphocytes against autologous brain tumor by crossreactive allo-tumor cell stimulation.
Topics: Aged; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antigens, CD; Antigens, Neoplasm; Autoant | 1997 |
NADPH/quinone oxidoreductase is a priority target of glioblastoma chemotherapy.
Topics: Antineoplastic Agents; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gli | 2000 |